Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT03737292

Liposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy

Led by Milton S. Hershey Medical Center · Updated on 2025-06-04

40

Participants Needed

1

Research Sites

390 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to assess pharmacokinetics of liposomal bupivacaine (Exparel) after multilevel intercostal injections of this local anesthetic for pain control during and after thoracoscopic surgeries. The specific aim of this study is to evaluate plasma concentration of bupivacaine after intraoperative intercostal injections of 266 mg of liposomal bupivacaine and compare it to plasma concentrations of bupivacaine after intercostal injections of 2mg/kg of 0.5% plain Bupivacaine with maximal dose of 30 ml or 150 mg. The hypothesis of the study is that plasma concentration of bupivacaine after intercostal injections of 266 mg of liposomal bupivacaine will be similar to concentrations after injections of plain bupivacaine, and will remain below the toxic level threshold range of 2000-3000 ng/mL (2-3 mg/L) at which central nervous system and cardiovascular adverse events would be expected to occur. The secondary objective is to evaluate if intercostal injections of 266 mg of liposomal bupivacaine will significantly reduce opioid consumption and postsurgical pain, within the first 48 hours and up to 3 months after minimally invasive thoracic surgeries, to determine if both acute and chronic post-thoracotomy pain can be decreased by intraoperative intercostal injections of liposomal bupivacaine. Additionally, the rate of pneumonia, the rate of atrial fibrillation and length of hospital stay will be assessed as secondary outcomes after thoracic surgeries. These outcomes can be affected by the level of postoperative pain and inflammation. Significance of this study: If positive, the results of this research have the potential to significantly improve pain management after thoracoscopic surgery. Based on prior experience, prolonged analgesia after liposomal bupivacaine injection is safe, and may help reduce perioperative opioid consumption and decrease opioid related complications. It will improve patient comfort, eliminate need for indwelling neuraxial catheters and risks associated with them.

CONDITIONS

Official Title

Liposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female patients over age 18 undergoing minimally invasive thoracic surgeries including VATS wedge resection/segmentectomy, VATS lobectomy, robot-assisted thoracoscopic wedge resection/segmentectomy, or robot-assisted thoracoscopic lobectomy procedures
Not Eligible

You will not qualify if you...

  • Patients under 18 years of age
  • Patients weighing less than 48 kg
  • Pregnant and lactating females
  • Patients taking narcotics for chronic pain near the surgical site
  • Patients with previous ipsilateral thoracic surgery
  • Patients undergoing pleurectomy or mechanical pleurodesis
  • Patients likely to convert from thoracoscopic procedure to open thoracotomy
  • Patients with pre-existing painful conditions such as CRIPS, fibromyalgia, or neuropathy
  • Patients unable to reliably communicate pain scores, including those with dementia or altered mental status
  • Patients with hypersensitivity to local anesthetics or study pain medications
  • Patients with previous thoracic spine surgeries
  • Patients with elevated creatinine levels over 1.5 mg/dl
  • Patients with liver dysfunction
  • Non-English speaking patients

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States, 17033

Actively Recruiting

Loading map...

Research Team

Z

Zoulfira Nisnevitch-Savarese, MD

CONTACT

C

Christopher Cowart, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Liposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | DecenTrialz